Summary
Gilead Sciences, Inc. (GILD) has filed an 8-K report on May 7, 2026, to announce its financial results for the first quarter ended March 31, 2026. The primary focus of this filing is the dissemination of these results, presented in both Generally Accepted Accounting Principles (GAAP) and non-GAAP measures. The company emphasizes that non-GAAP figures are provided for supplemental understanding and internal management purposes, with a reconciliation to GAAP figures available in the accompanying press release. Investors should note that while the press release provides key financial performance indicators, this specific 8-K filing, under Item 2.02 and Item 9.01, is not considered 'filed' for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into future filings. Therefore, investors should carefully review the full press release (Exhibit 99.1) for detailed financial performance and strategic insights.
Key Highlights
- 1Gilead Sciences announced its financial results for the first quarter ended March 31, 2026.
- 2The company presented its financial results using both GAAP and non-GAAP measures.
- 3Management views non-GAAP financial information as useful for investors and for internal operational, budgeting, and financial planning.
- 4A detailed reconciliation between GAAP and non-GAAP financial information is provided in the press release.
- 5The press release containing the detailed financial results is included as Exhibit 99.1 to this 8-K filing.
- 6The information furnished under Item 2.02 and Item 9.01 is not considered 'filed' for certain regulatory purposes and does not carry the liabilities associated with Section 18 of the Exchange Act.